Medios AG (ILM1) AI Stock Analysis

• Market Cap: €328.51M
• Dividend Yield: N/A
• Average Volume (3M): 45.40K
• Price to Earnings (P/E): 21.5
• Beta (1Y): 0.79
• Revenue Growth: 5.62%
• EPS Growth: -21.87%
• Country: DE
• Employees: 472
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Distribution
• EPS (TTM): 0.25
• Shares Outstanding: 25,505,724
• 10 Day Avg. Volume: 27,685
• 30 Day Avg. Volume: 45,398
• PEG Ratio: 1.42
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 12.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €22.26
• Price Target Upside: 81.26% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 76 Outperform
• Price Target: €14.50 ▲(18.08%Upside)

Medios AG displays strong financial performance with robust revenue growth and operational efficiency, which are the primary strengths supporting the stock score. Technical analysis indicates mild bullish sentiment, but the potential for short-term volatility exists due to oversold conditions. Valuation is limited by the absence of key metrics, which introduces uncertainty. Overall, the company's stable financial foundation is the most significant factor, though investors should remain aware of potential valuation risks.

Positive Factors

International Expansion

The internationalisation strategy of Medios is showing promising results with the successful integration of the Ceban acquisition.

Regulatory Environment

Higher profitability appears sustainable due to a more liberal regulatory framework in the Netherlands, giving the company greater entrepreneurial freedom.

Negative Factors

Earnings Forecast

Higher M&A-related one-offs, increased depreciation, and a higher tax rate have resulted in a lower EPS forecast.

Medios AG Business Overview & Revenue Model

Company Description

Medios AG (ILM1) is a prominent player in the German pharmaceutical sector, specializing in the provision of specialty pharmaceuticals and related services. The company focuses on the distribution and logistics of specialty drugs which require specific handling and storage due to their complex nature. Medios AG serves a broad spectrum of clients including pharmacies, healthcare professionals, and hospitals, ensuring the safe and efficient delivery of high-value medications.

How the Company Makes Money

Medios AG generates revenue primarily through the distribution and logistics services of specialty pharmaceuticals. The company's key revenue streams include the sale of high-value specialty drugs to pharmacies and healthcare facilities. Medios AG leverages its advanced logistics infrastructure to manage the supply chain of these pharmaceuticals, ensuring timely and safe delivery. Additionally, the company may engage in strategic partnerships with pharmaceutical manufacturers to enhance its product offerings and expand its market reach. The robust demand for specialty medications, driven by the growing prevalence of chronic diseases and personalized medicine, significantly contributes to the company's earnings.

Medios AG Financial Statement Overview

Summary

Medios AG demonstrates strong financial health with consistent revenue growth, improved gross and EBITDA margins, a robust balance sheet with low leverage, and efficient cash generation marked by substantial free cash flow growth. However, the slight decline in net profit margin and significant investing cash outflows are potential concerns.

Income Statement

Medios AG has demonstrated a consistent upward trend in revenue, with a notable revenue growth rate of 5.51% from 2023 to 2024. The company's gross profit margin improved to 8.04% in 2024 from 6.09% in 2023, indicating better cost management. However, the net profit margin decreased slightly to 0.67% from 1.05%, suggesting a dip in overall profitability potentially due to increased operational costs or taxation. The EBIT margin remained stable at around 1.68%, while the EBITDA margin improved from 2.96% to 3.40%, showcasing enhanced operational efficiency.

Balance Sheet

The balance sheet reflects strong equity growth, with stockholders' equity increasing to €510.19 million in 2024. The debt-to-equity ratio remains low at 0.47, indicating prudent leverage usage. The return on equity (ROE) is modest at 2.46%, but it indicates a reasonable return on shareholders' investments. The equity ratio stands at 54.60%, showcasing a robust capital structure with more than half of the assets financed by equity, implying financial stability.

Cash Flow

Medios AG shows a substantial increase in free cash flow to €67.36 million in 2024 from €15.14 million in 2023, representing significant free cash flow growth. The operating cash flow to net income ratio is strong at 5.87, indicating efficient cash generation relative to net income. However, the large increase in free cash flow is partially offset by substantial investing cash outflows, which could imply significant reinvestment or capital expenditures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.91B	1.88B	1.78B	1.61B	1.36B	626.54M
Gross Profit	154.37M	151.46M	108.63M	106.87M	68.48M	37.58M
EBITDA	74.20M	64.00M	52.82M	51.33M	34.68M	13.12M
Net Income	14.94M	12.55M	18.81M	18.33M	7.40M	5.53M
Balance Sheet
Total Assets	929.17M	934.36M	594.75M	575.96M	524.14M	194.54M
Cash, Cash Equivalents and Short-Term Investments	89.34M	106.00M	71.04M	79.21M	168.43M	19.79M
Total Debt	221.58M	238.37M	17.15M	17.63M	49.71M	19.23M
Total Liabilities	412.38M	424.17M	125.95M	127.91M	129.98M	52.11M
Stockholders Equity	516.79M	510.19M	468.81M	448.05M	394.16M	142.43M
Cash Flow
Free Cash Flow	26.75M	67.36M	15.14M	32.06M	48.70M	-42.98M
Operating Cash Flow	33.14M	73.67M	16.41M	37.12M	61.52M	-38.12M
Investing Cash Flow	-221.50M	-222.28M	-16.57M	-86.54M	17.36M	-5.88M
Financing Cash Flow	164.08M	183.80M	-8.01M	-39.80M	69.76M	51.14M

Medios AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.28
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:ILM1, the sentiment is Negative. The current price of 12.28 is below the 20-day moving average (MA) of 12.57, above the 50-day MA of 12.20, and below the 200-day MA of 12.70, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 46.98 is Neutral, neither overbought nor oversold. The STOCH value of 12.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:ILM1.

Medios AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ILM1	76 Outperform	€328.51M	21.53	2.99%	―	5.62%	-21.87%
PSG	75 Outperform	€355.20M	17.66	48.46%	1.72%	13.80%	10.94%
SBS	70 Outperform	€351.91M	21.97	6.73%	2.04%	-1.64%	22.60%
M12	68 Neutral	€253.65M	15.73	14.61%	3.68%	7.23%	58.37%
Sector *	66 Neutral	€6.57B	18.46	-1.30%	2.26%	-0.22%	-36.66%
FYB	62 Neutral	€524.63M	5.89	-26.06%	―	-10.32%	-250.76%
HPHA	56 Neutral	€217.63M	―	-78.11%	―	-56.07%	-78.48%